Semaglutide Dose For Weight Loss: Personalized Dosing Guide

Last reviewed: May 27, 2026

Last updated: May 27, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Semaglutide dosing for weight loss follows a stepwise escalation protocol, starting at 0.25 mg weekly and increasing every four weeks until reaching an effective maintenance dose, typically between 1.7 mg and 2.4 mg weekly. Clinical trials demonstrate that this gradual approach balances tolerability with weight loss efficacy, reducing gastrointestinal side effects while maintaining therapeutic benefit.

Determining the right semaglutide dose is not one-size-fits-all. Individual factors—including baseline metabolic health, GLP-1 receptor sensitivity, and genetic variation in peptide pathways—can influence how your body responds to dosing escalation. Understanding these variables helps frame conversations with your healthcare provider about your personalized treatment plan.

Standard Semaglutide Dosing Protocol and Clinical Evidence

The FDA-approved semaglutide dosing schedule for weight loss begins at 0.25 mg subcutaneously once weekly for four weeks. The dose then increases by 0.25 mg every four weeks—moving through 0.5 mg, 1.0 mg, 1.7 mg, and finally 2.4 mg—until therapeutic goals or side effect tolerability is reached. This gradual titration allows your body to adapt to the medication's effects.

Clinical evidence from the STEP trials showed that participants achieving the 2.4 mg maintenance dose experienced approximately 15–17% body weight reduction over 68 weeks compared to placebo. However, not all patients require the maximum dose to achieve meaningful weight loss. Some individuals respond effectively at 1.7 mg weekly, making individualized dose adjustment essential for both safety and efficacy outcomes.

How Individual Factors Influence Your Optimal Dosing Response

Your optimal semaglutide dose depends on multiple interconnected factors: GLP-1 receptor density and sensitivity, baseline fasting glucose and insulin levels, gastrointestinal motility status, liver and kidney function, current medications, and genetic variation in peptide-signaling pathways. Providers assess these variables to determine whether standard titration fits your profile or whether modified dosing is warranted.

Dosing Factor	Clinical Relevance to Weight Loss Response
GLP-1R Genetic Variants	Variations in GLP1R gene (e.g., rs6923761) may correlate with receptor sensitivity and medication response kinetics, supporting dose personalization.
Baseline Metabolic State	Patients with higher fasting insulin or insulin resistance may show dose-dependent response differences; some benefit from slower titration or intermediate maintenance doses.
Gastrointestinal Status	History of gastroparesis or delayed gastric emptying may warrant slower escalation or lower maintenance dose to minimize nausea and constipation.
Renal and Hepatic Function	Normal kidney and liver function support standard dosing; compromised function may require dose modification or closer monitoring per provider guidance.
Concurrent Medications	Drugs affecting glucose metabolism, appetite, or GI motility (e.g., other diabetes medications, antidepressants) may interact with semaglutide dosing effects.

When to Pause, Adjust, or Escalate Your Semaglutide Dose

Your healthcare provider may recommend slowing dose escalation—or pausing at a lower maintenance dose—if you experience persistent nausea, vomiting, constipation, or loss of appetite disproportionate to weight loss benefit. These symptoms often resolve with dose adjustment; stopping abruptly is not advised without provider guidance, as rebound weight gain is common.

Conversely, if you tolerate escalation well but see minimal weight loss progress after 4–8 weeks at a given dose, your provider may recommend continuing the titration schedule toward 2.4 mg. Some patients plateau at intermediate doses (e.g., 1.7 mg) with excellent outcomes; others require the maximum dose for meaningful response. This individualization is normal and reflects your unique pharmacokinetics and body composition goals.

Safety Considerations and Eligibility for Semaglutide Dosing

Semaglutide is not appropriate for all patients. Contraindications include personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, pregnancy, severe kidney or liver disease, and active diabetic retinopathy. Your provider must screen for these conditions before recommending semaglutide, regardless of planned dose. Those with pancreatitis history require special caution and close monitoring during titration.

During dose escalation, monitor for warning signs: severe abdominal pain (pancreatitis risk), vision changes (retinopathy concern), rapid heart rate, severe dehydration, or persistent vomiting. Report these to your provider immediately. Regular follow-up visits—typically every 4–8 weeks during titration—allow your provider to assess tolerability, measure weight loss progress, and adjust your dose if needed to optimize safety and outcomes.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test examines key variants in GLP-1 receptor and related metabolic pathways—including GLP1R rs6923761, GIPR rs1800437, FTO rs9939609, and MC4R rs17782313—to help identify genetic predispositions that may influence how your body responds to semaglutide dosing and escalation. This genetic context may help provide useful information for your provider's dosing strategy, though genetic variants do not predict exact medication response.

The test reveals whether you carry genetic variations associated with GLP-1 receptor sensitivity, appetite regulation, and fat metabolism. These predispositions can inform discussions about starting dose, expected titration speed, and maintenance dose targets. For example, certain GLP1R variants correlate with varying degrees of receptor responsiveness, which may help your provider anticipate whether you'll respond optimally at lower or higher doses within the standard range.

Using genetic insights alongside clinical assessment—your current weight, metabolic markers, side effect history, and goals—can support a more informed conversation with your provider about your personalized semaglutide dosing plan. This integrated approach aligns dosing strategy with your individual biology, potentially improving efficacy while managing side effects proactively. Always interpret genetic results with your healthcare team; they guide clinical decision-making, not replace it.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

What is the starting dose of semaglutide for weight loss?

The standard starting dose is 0.25 mg subcutaneously once weekly. Your provider increases this by 0.25 mg every four weeks, typically reaching 1.7–2.4 mg as maintenance. The exact escalation pace depends on your tolerability and response.

Do all patients need to reach the 2.4 mg dose for weight loss?

No. Clinical trials show meaningful weight loss at 1.7 mg for many patients. Your provider may recommend stopping at an intermediate dose if you achieve your goals and tolerate it well, or continuing to 2.4 mg if additional weight loss is desired and side effects remain manageable.

How does PlexusDx help with semaglutide dosing decisions?

PlexusDx's Precision Peptide Genetic Test identifies GLP-1 receptor and metabolic gene variants that may correlate with medication response patterns. This genetic context, combined with clinical assessment, can help your provider personalize your starting dose and escalation strategy.

What side effects might indicate I need a slower dose escalation?

Persistent nausea, vomiting, severe constipation, loss of appetite, or abdominal discomfort may suggest your body needs more time to adjust. Discuss these with your provider; dose escalation can be paused or slowed to improve tolerability while maintaining weight loss progress.

Can genetic predispositions predict my exact semaglutide dose?

Genetic variants can provide context about receptor sensitivity and metabolic patterns, but they do not predict your exact optimal dose. Your provider weighs genetic insights alongside your clinical history, current health, and response during titration to determine your personalized dose.

Semaglutide Dose For Weight Loss: Biomarkers, Genetics, and Provider-Guided Optimization